This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignee: Dana-Farber-Cancer Institute Inc.. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: The Innovative Contributions of Sarah Derks
Introduction
Sarah Derks is a prominent inventor based in Boston, MA, known for her significant contributions to the field of cancer research. She has made strides in understanding the responsiveness of esophagogastric cancers to specific treatments. Her work is vital in the ongoing battle against cancer, particularly in improving patient outcomes.
Latest Patents
Sarah holds a patent for "PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers." This invention is groundbreaking as it identifies novel biomarkers that can predict how well patients with esophagogastric cancers will respond to inhibitors of the PD-1 pathway. This advancement has the potential to enhance personalized treatment strategies for cancer patients.
Career Highlights
Sarah Derks is affiliated with the Dana-Farber Cancer Institute Inc., where she collaborates with leading experts in the field. Her work at this prestigious institution underscores her commitment to advancing cancer research and treatment.
Collaborations
Throughout her career, Sarah has worked alongside notable colleagues, including Gordon James Freeman and Scott J Rodig. These collaborations have further enriched her research and contributed to the development of innovative solutions in cancer treatment.
Conclusion
In summary, Sarah Derks is a dedicated inventor whose work in identifying biomarkers for cancer treatment is making a significant impact. Her contributions are paving the way for more effective therapies and improved patient care in the fight against cancer.